Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trialsPaul W. Noble, Roland M. du Bois, Dominique Valeyre et al.|The Lancet|2011Cited by 2.1k
Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trialTalmadge E. King, Roland M. du Bois, Carlo Albera et al.|The Lancet|2009Cited by 530
Six-Minute-Walk Test in Idiopathic Pulmonary Fibrosis: Test Validation and Minimal Clinically Important DifferenceRoland M. du Bois, Talmadge E. King, Derek Weycker et al.|American Journal of Respiratory and Critical Care Medicine|2010Cited by 457
Ascertainment of Individual Risk of Mortality for Patients with Idiopathic Pulmonary FibrosisRoland M. du Bois, Talmadge E. King, Derek Weycker et al.|American Journal of Respiratory and Critical Care Medicine|2011Cited by 429
A Randomized Phase 3 Study Comparing Once-Daily Elvitegravir With Twice-Daily Raltegravir in Treatment-Experienced Subjects With HIV-1 infectionRichard Elion, Javier Szwarcberg, Jean‐Michel Molina et al.|JAIDS Journal of Acquired Immune Deficiency Syndromes|2013Cited by 41